Christina S. Baik

Also affiliated with University of Washington, University of Washington Medical Center, Fred Hutch Cancer Center, University of Washington Applied Physics Laboratory

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study”.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00064-0

N/A

3.7DataRank · unranked

164 citations

Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares +15 more

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist(2022)10.1093/oncolo/oyac080

N/A

1.7DataRank · unranked

49 citations

Christina S. Baik, Jessica R. Bauman, Jill Gilbert, Marcia S. Brose, Juneko E. Grilley‐Olson +13 more

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of Oncology(2022)10.1016/j.annonc.2022.08.002

N/A

0.782DataRank · unranked

183 citations

Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.11.020

N/A

0.494DataRank · unranked

26 citations

Robyn Du, Nathaniel J. Myall, Whitney E. Lewis, Natalie Uy, Lingzhi Hong +22 more

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.e18063

N/A

0DataRank · unranked

1 citations

Vicky Wu, Kevin Ng, Jenna Voutsinas, Ariana Dumenigo‐Jimenez, Jonathan R. Fromm +15 more

Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.06.015

N/A

0DataRank · unranked

13 citations

Tejas Patil, Kedar Kirtane, Thereasa A. Rich, Carin R. Espenschied, Caroline Weipert +5 more

Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer

medRxiv(2025)10.1101/2025.03.10.25323586

N/A

0DataRank · unranked

0 citations

Christina S. Baik, Joel W. Neal, Fangdi Sun, Rafael Santana-Dávila, Sylvia Lee +13 more

Prognostic role of mid-treatment PET/CT and plasma cytokines in patients undergoing chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9040

N/A

0DataRank · unranked

0 citations

Ramesh Rengan, Christina S. Baik, Keith D. Eaton, Bernardo H. L. Goulart, Sylvia Lee +9 more

Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

Advances in Radiation Oncology(2021)10.1016/j.adro.2021.100857

N/A

0DataRank · unranked

4 citations

Daniel S. Hippe, Hannah Thomas, Balukrishna Sasidharan, Paul D. Lampe, Christina S. Baik +12 more

Prognostic value and peripheral immunologic correlates of early FDG PET response imaging in a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer

medRxiv(2021)10.1101/2021.02.22.21251919

N/A

0DataRank · unranked

1 citations

Daniel S. Hippe, Hannah Thomas, Balukrishna Sasidharan, Paul D. Lampe, Christina S. Baik +12 more

A qualitative study of interactions with oncologists among patients with advanced lung cancer

Supportive Care in Cancer(2022)10.1007/s00520-022-07309-7

N/A

0DataRank · unranked

2 citations

Upal Basu Roy, Eugene Manley, Maisha Standifer, Christina S. Baik, Casey Walsh +1 more

Peripheral blood T-cell receptor repertoire profiling of advanced non-small cell lung cancer patients receiving PD-1/PD-L1 treatment.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21004

N/A

0DataRank · unranked

0 citations

Shin‐Heng Chiou, Viswam S. Nair, Renato Martins, Rafael Santana-Dávila, Sylvia Lee +4 more